Aakanksha Khandelwal

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 207 citations

Lymphoid Neoplasia, Translational Medicine, Hodgkin Lymphoma +12

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1<i>H</i>-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

Tadas S. Vasaitis, Aashvini Belosay, Adam Schayowitz et al. · Molecular Cancer Therapeutics · 2008 · 134 citations · Full text

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

Lalji K. Gediya, Aashvini Belosay, Aakanksha Khandelwal et al. · Bioorganic & Medicinal Chemistry · 2007 · 50 citations · Full text

Tumor Xenografts, Inhibitory Effects, Oncology +9

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Kerry L. Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli et al. · Journal for ImmunoTherapy of Cancer · 2021 · 42 citations · Full text

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth

Jyoti Patel, Jhalak Mehta, Aashvini Belosay et al. · British Journal of Cancer · 2007 · 40 citations · Full text

Tumour Growth, Medicine, Cancer Cell Biology +14